Showing results (51-60 of 76) with videos related to

Sort By:
Pageof 8
Stroke|October 24, 2009
Patient dissatisfaction with acute stroke careKjell Asplund, Fredrik Jonsson, Marie Eriksson, et al.
Pharmacoeconomics|June 28, 2006
Lifetime health consequences and cost-effectiveness of rosiglitazone in combination with metformin for the treatment of type 2 diabetes in SpainArran T Shearer, Adrian Bagust, F Javier Ampudia-Blasco, et al.
Pharmacoeconomics|October 12, 2013
Vemurafenib for the treatment of locally advanced or metastatic BRAF V600 mutation-positive malignant melanoma: a NICE single technology appraisalSophie Beale, Rumona Dickson, Adrian Bagust, et al.
Stroke|June 2, 2007
Beyond conventional stroke guidelines: setting prioritiesBo Norrving, Per Wester, Katharina Stibrant Sunnerhagen, et al.
Pharmacoeconomics|May 15, 2010
Cetuximab for recurrent and/or metastatic squamous cell carcinoma of the head and neck: a NICE single technology appraisalAdrian Bagust, Janette Greenhalgh, Angela Boland, et al.
Pharmacoeconomics - Open|February 12, 2019
Eribulin for Treating Locally Advanced or Metastatic Breast Cancer After One Chemotherapy Regimen: An Evidence Review Group Perspective of a NICE Single Technology AppraisalNigel Fleeman, Adrian Bagust, Rui Duarte, et al.
Stroke|March 6, 2004
Self-reported depression and use of antidepressants after stroke: a national surveyMarie Eriksson, Kjell Asplund, Eva-Lotta Glader, et al.
Pharmacoeconomics|April 24, 2015
Dabrafenib for Treating Unresectable, Advanced or Metastatic BRAF V600 Mutation-Positive Melanoma: An Evidence Review Group PerspectiveNigel Fleeman, Adrian Bagust, Sophie Beale, et al.
Pharmacoeconomics|March 31, 2018
Paclitaxel as Albumin-Bound Nanoparticles with Gemcitabine for Untreated Metastatic Pancreatic Cancer: An Evidence Review Group Perspective of a NICE Single Technology AppraisalAngela Stainthorpe, Janette Greenhalgh, Adrian Bagust, et al.
Pharmacoeconomics|November 28, 2017
Pegylated Liposomal Irinotecan Hydrochloride Trihydrate for Treating Pancreatic Cancer After Gemcitabine: An Evidence Review Group Perspective of a NICE Single Technology AppraisalNigel Fleeman, Ahmed Abdulla, Adrian Bagust, et al.
Pageof 8